Somnath Mukherjee is a Consultant Clinical Oncologist based at Oxford University Hospital NHS Foundation Trust with special interest in radiation therapy for gastro-oesophageal and hepatobiliary cancers, Stereotactic and MRI guided radiotherapy.
Somnath became a consultant oncologist since 2004, and have worked at Velindre Cancer Centre, Cardiff and Northampton Centre of Oncology, before moving to Oxford in 2012. He leads the upper GI and pancreatic radiation services at Oxford University Hospital, prior to which he led the pancreas services in Cardiff and upper GI service in Northampton.
Somnath is well known for his research contribution in oesophageal and pancreatic cancer radiotherapy. He has been involved as co-investigator or lead investigator in several of the key CRUK funded multi-centre trials of oesophageal cancer radiotherapy in the UK, including SCOPE, SCOPE2, NEOSCOPE and CYTOFLOC. He has contributed to development of national radiation guidelines, has been a member of the Oesophago-gastric subgroup of NCRI, and has served as clinical expert in NICE Technology Appraisal committee for oesophageal cancer therapeutics.
Somnath has also led several large multi-centre trials in pancreatic cancer radiation (SCALOP, SCALOP2) which has helped develop radiotherapy as a treatment option for pancreatic cancer in the UK. He has been actively involved in the NHS England commissioning of Stereotactic RT for pancreatic cancer. He is a member of the NCRI pancreatic subgroup, has served as member of the NICE committee for Pancreatic Cancer guideline committee and quality standard committee, and a contributor to the current ASCO locally advanced pancreatic cancer guidelines and the European pancreatic cancer radiotherapy guidelines. He was awarded Associate Professorship of Oxford University in July 2016.